​

Alkermes (ALKS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALKS Stock Forecast

Alkermes stock forecast is as follows: an average price target of $37.50 (represents a 26.22% upside from ALKS’s last price of $29.71) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.

ALKS Price Target

The average price target for Alkermes (ALKS) is $37.50 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $36.00. This represents a potential 26.22% upside from ALKS's last price of $29.71.

ALKS Analyst Ratings

Hold

According to 9 Wall Street analysts, Alkermes's rating consensus is 'Hold'. The analyst rating breakdown for ALKS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (44.44%), 5 'Hold' (55.56%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Alkermes Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024David AmsellemPiper Sandler$37.00$31.2518.40%24.54%
Nov 13, 2024Vamil DivanMizuho Securities$40.00$26.0753.43%34.63%
Nov 04, 2024Paul MatteisStifel Nicolaus$36.00$26.5935.39%21.17%
Oct 24, 2024Paul MatteisStifel Nicolaus$25.00$26.85-6.89%-15.85%
Oct 14, 2024Douglas TsaoH.C. Wainwright$37.00$28.9127.98%24.54%
Apr 10, 2024Akash TewariJefferies$25.00$13.3786.99%-15.85%
Apr 09, 2024Vamil DivanMizuho Securities$35.00$26.7330.94%17.81%
Apr 09, 2024Akash TewariJefferies$25.00$26.95-7.24%-15.85%
Mar 18, 2024Joel BeattyRobert W. Baird$37.00$27.5334.40%24.54%
Dec 06, 2022J.P. Morgan$29.00$25.0015.98%-2.39%
Apr 28, 2022Leerink Partners$27.00$30.38-11.13%-9.12%
Apr 21, 2022Leerink Partners$25.00$29.40-14.97%-15.85%
Apr 20, 2022Goldman Sachs$35.00$28.4822.89%17.81%

The latest Alkermes stock forecast, released on Dec 05, 2024 by David Amsellem from Piper Sandler, set a price target of $37.00, which represents a 18.40% increase from the stock price at the time of the forecast ($31.25), and a 24.54% increase from ALKS last price ($29.71).

Alkermes Price Target by Period

1M3M12M
# Anlaysts159
Avg Price Target$37.00$35.00$33.00
Last Closing Price$29.71$29.71$29.71
Upside/Downside24.54%17.81%11.07%

In the current month, the average price target of Alkermes stock is $37.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 24.54% increase as opposed to Alkermes's last price of $29.71. This month's average price target is up 5.71% compared to last quarter, and up 12.12% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024H.C. WainwrightNeutralNeutralHold
Oct 14, 2024H.C. WainwrightBuyBuyHold
Oct 10, 2024Cantor FitzgeraldUnderperformUnderperformHold
Oct 10, 2024J.P. MorganNeutralNeutralHold
Sep 23, 2024JefferiesBuyBuyHold
Jul 25, 2024H.C. WainwrightNeutralNeutralHold
Jul 15, 2024H.C. WainwrightBuyBuyHold
Jul 15, 2024Cowen & Co.UnderperformUnderperformHold
Jun 17, 2024Piper SandlerBuyBuyHold
Jun 17, 2024Cowen & Co.BuyInitialise
Jun 04, 2024JefferiesBuyBuyHold
May 23, 2024JefferiesUnderperformUnderperformHold
May 23, 2024Piper SandlerBuyBuyHold
May 22, 2024Cantor FitzgeraldOverweightOverweightHold
May 02, 2024UBSBuyBuyHold
May 02, 2024Bank of America SecuritiesNeutralNeutralHold
Apr 09, 2024UBSBuyBuyHold
Apr 09, 2024JefferiesBuyBuyHold
Mar 19, 2024UBSNeutralNeutralHold
Oct 24, 2023Evercore ISIOutperformUpgrade
Dec 19, 2022Piper SandlerOverweightOverweightHold
Nov 03, 2022Piper SandlerOverweightUpgrade
Oct 14, 2022NeedhamNeutralUpgrade
Oct 14, 2022Bank of America SecuritiesNeutralUpgrade
Apr 28, 2022SVB LeerinkMarket PerformMarket PerformHold

Alkermes's last stock rating was published by H.C. Wainwright on Oct 14, 2024. The company gave ALKS a "Neutral" rating, the same as its previous rate.

Alkermes Financial Forecast

Alkermes Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$377.48M-$617.40M$287.60M$304.67M$252.36M$276.22M$278.55M$324.46M$294.14M$303.72M$251.43M$280.00M$265.01M$247.53M$246.22M$412.73M$255.24M$279.87M$223.10M$225.15M$191.78M
Avg Forecast$371.70M$356.34M$352.61M$325.63M$380.71M$380.88M$393.30M$360.26M$362.22M$362.31M$458.07M$283.41M$289.76M$271.41M$268.97M$256.02M$306.55M$301.38M$275.94M$235.23M$268.63M$238.39M$232.70M$228.27M$404.45M$252.65M$252.45M$216.79M$175.16M$95.90M
High Forecast$389.69M$373.59M$369.68M$348.86M$396.39M$383.46M$393.30M$367.20M$387.95M$379.77M$480.24M$297.13M$303.79M$271.41M$268.97M$256.02M$306.55M$301.38M$275.94M$235.23M$268.63M$238.39M$232.70M$228.27M$404.45M$252.65M$252.45M$216.79M$210.19M$115.08M
Low Forecast$346.66M$332.34M$328.86M$310.59M$357.07M$378.30M$393.30M$353.31M$335.98M$339.26M$427.21M$264.32M$270.24M$271.41M$268.97M$256.02M$306.55M$301.38M$275.94M$235.23M$268.63M$238.39M$232.70M$228.27M$404.45M$252.65M$252.45M$216.79M$140.12M$76.72M
# Analysts333510934796437434744459644741111
Surprise %--------1.04%-1.35%1.01%1.05%0.93%1.03%1.09%1.06%0.98%1.10%1.07%1.04%1.11%1.06%1.08%1.02%1.01%1.11%1.03%1.29%2.00%

Alkermes's average Quarter revenue forecast for Mar 24 based on 4 analysts is $360.26M, with a low forecast of $353.31M, and a high forecast of $367.20M. ALKS's average Quarter revenue forecast represents a -4.56% decrease compared to the company's last Quarter revenue of $377.48M (Dec 23).

Alkermes EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333510934796437434744459644741111
EBITDA--------$54.63M-$239.19M$-33.77M$-7.75M$-40.67M$-12.36M$-4.38M$13.00M$-4.71M$26.54M$4.96M$-19.45M$24.58M$-3.30M$-7.86M$21.15M$-30.13M$-16.95M$-77.11M$-35.79M$-46.06M
Avg Forecast$31.41M$30.11M$29.80M$27.52M$32.17M$32.19M$33.24M$-184.51M$30.61M$30.62M$38.71M$-197.34M$149.06M$4.03M$3.99M$-211.06M$4.55M$4.47M$4.10M$33.48M$3.99M$3.54M$3.45M$-15.33M$6.00M$3.75M$3.75M$-91.80M$-25.57M$-50.68M
High Forecast$32.93M$31.57M$31.24M$29.48M$33.50M$32.41M$33.24M$-147.61M$32.79M$32.09M$40.58M$-157.87M$178.88M$4.03M$3.99M$-168.85M$4.55M$4.47M$4.10M$40.18M$3.99M$3.54M$3.45M$-12.26M$6.00M$3.75M$3.75M$-73.44M$-20.45M$-40.54M
Low Forecast$29.30M$28.09M$27.79M$26.25M$30.18M$31.97M$33.24M$-221.42M$28.39M$28.67M$36.10M$-236.81M$119.25M$4.03M$3.99M$-253.27M$4.55M$4.47M$4.10M$26.78M$3.99M$3.54M$3.45M$-18.39M$6.00M$3.75M$3.75M$-110.16M$-30.68M$-60.82M
Surprise %--------1.78%-6.18%0.17%-0.05%-10.10%-3.10%0.02%2.86%-1.05%6.48%0.15%-4.88%6.95%-0.95%0.51%3.52%-8.04%-4.52%0.84%1.40%0.91%

4 analysts predict ALKS's average Quarter EBITDA for Mar 24 to be $-184.51M, with a high of $-147.61M and a low of $-221.42M. This is -437.74% lower than Alkermes's previous annual EBITDA (Dec 23) of $54.63M.

Alkermes Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333510934796437434744459644741111
Net Income--------$160.55M-$237.06M$-41.84M$-28.25M$-63.97M$-30.14M$-35.90M$873.00K$-28.99M$2.36M$-22.42M$-42.64M$-134.00K$-29.43M$-38.65M$-5.35M$-52.88M$-41.99M$-96.40M$-62.51M$-68.88M
Avg Forecast$80.59M$76.41M$73.16M$64.81M$124.61M$117.00M$117.59M$-282.49M$74.73M$66.15M$61.33M$-302.12M$5.47M$4.73M$1.14M$-323.13M$12.70M$9.94M$18.79M$-151.32M$10.55M$317.85K$1.01M$-75.38M$99.07M$-32.74M$-17.25M$-114.76M$-44.64M$-75.79M
High Forecast$85.66M$81.22M$77.76M$90.43M$148.92M$119.80M$120.01M$-225.99M$97.48M$75.38M$65.19M$-241.70M$6.57M$4.73M$1.14M$-258.50M$12.70M$9.94M$18.79M$-121.06M$10.55M$317.85K$1.01M$-60.30M$99.07M$-32.74M$-17.25M$-91.81M$-35.71M$-60.63M
Low Forecast$73.53M$69.72M$66.75M$51.24M$91.18M$114.20M$115.17M$-338.98M$55.24M$47.69M$55.96M$-362.55M$4.38M$4.73M$1.14M$-387.75M$12.70M$9.94M$18.79M$-181.59M$10.55M$317.85K$1.01M$-90.45M$99.07M$-32.74M$-17.25M$-137.71M$-53.57M$-90.95M
Surprise %--------2.15%-3.87%0.14%-5.16%-13.52%-26.54%0.11%0.07%-2.92%0.13%0.15%-4.04%-0.42%-29.10%0.51%-0.05%1.61%2.43%0.84%1.40%0.91%

Alkermes's average Quarter net income forecast for Mar 24 is $-282.49M, with a range of $-338.98M to $-225.99M. ALKS's average Quarter net income forecast represents a -275.95% decrease compared to the company's last Quarter net income of $160.55M (Dec 23).

Alkermes SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333510934796437434744459644741111
SG&A--------$169.79M-$205.26M$174.48M$157.54M$152.78M$150.38M$145.05M$160.41M$136.21M$139.19M$125.17M$145.78M$127.65M$132.03M$133.37M$154.45M$148.70M$155.07M$141.22M$118.15M$102.10M
Avg Forecast$183.48M$175.90M$174.06M$160.74M$187.93M$188.01M$194.14M$177.83M$178.80M$178.84M$226.11M$139.90M$143.03M$133.97M$132.77M$126.37M$151.32M$148.77M$136.21M$116.11M$132.60M$117.67M$114.87M$112.68M$199.64M$124.71M$124.61M$168.12M$84.39M$47.34M
High Forecast$192.36M$184.41M$182.48M$172.20M$195.66M$189.28M$194.14M$181.26M$191.50M$187.46M$237.05M$146.67M$149.95M$133.97M$132.77M$126.37M$151.32M$148.77M$136.21M$116.11M$132.60M$117.67M$114.87M$112.68M$199.64M$124.71M$124.61M$201.74M$101.27M$56.81M
Low Forecast$171.12M$164.05M$162.33M$153.31M$176.26M$186.74M$194.14M$174.40M$165.84M$167.47M$210.88M$130.47M$133.40M$133.97M$132.77M$126.37M$151.32M$148.77M$136.21M$116.11M$132.60M$117.67M$114.87M$112.68M$199.64M$124.71M$124.61M$134.50M$67.51M$37.87M
Surprise %--------0.95%-0.91%1.25%1.10%1.14%1.13%1.15%1.06%0.92%1.02%1.08%1.10%1.08%1.15%1.18%0.77%1.19%1.24%0.84%1.40%2.16%

Alkermes's average Quarter SG&A projection for Mar 24 is $177.83M, based on 4 Wall Street analysts, with a range of $174.40M to $181.26M. The forecast indicates a 4.74% rise compared to ALKS last annual SG&A of $169.79M (Dec 23).

Alkermes EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts333510934796437434744459644741111
EPS--------$0.96-$1.43$-0.25$-0.17$-0.39$-0.18$-0.22$0.01$-0.18$0.01$-0.14$-0.27$-0.00$-0.19$-0.24$-0.03$-0.34$-0.27$-0.62$-0.40$-0.45
Avg Forecast$0.48$0.46$0.44$0.39$0.75$0.70$0.70$0.58$0.45$0.40$0.37-$0.04$0.03$0.01$0.02$0.07$0.06$0.11$-0.01$0.06-$0.01$-0.04$0.58$-0.19$-0.10$-0.19$-0.05$-0.10
High Forecast$0.51$0.49$0.47$0.54$0.89$0.72$0.72$0.61$0.58$0.45$0.39-$0.04$0.03$0.01$0.02$0.07$0.06$0.11$-0.01$0.06-$0.01$-0.04$0.58$-0.19$-0.10$-0.19$-0.04$-0.08
Low Forecast$0.44$0.42$0.40$0.31$0.55$0.68$0.69$0.56$0.33$0.29$0.34-$0.04$0.03$0.01$0.02$0.07$0.06$0.11$-0.01$0.06-$0.01$-0.04$0.58$-0.19$-0.10$-0.19$-0.06$-0.12
Surprise %--------2.15%-3.89%-55.99%-4.06%-14.09%-27.11%-9.47%0.07%-3.10%0.09%10.04%-4.38%-0.43%-32.12%5.53%-0.06%1.78%2.68%3.28%8.00%4.50%

According to 4 Wall Street analysts, Alkermes's projected average Quarter EPS for Mar 24 is $0.58, with a low estimate of $0.56 and a high estimate of $0.61. This represents a -39.30% decrease compared to ALKS previous annual EPS of $0.96 (Dec 23).

Alkermes Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IRWDIronwood Pharmaceuticals$3.53$8.50140.79%Buy
DVAXDynavax$12.90$29.00124.81%Buy
EOLSEvolus$11.73$24.00104.60%Buy
AMPHAmphastar Pharmaceuticals$40.85$66.0061.57%Buy
ANIPANI Pharmaceuticals$55.83$79.0041.50%Buy
COLLCollegium Pharmaceutical$30.90$42.3336.99%Buy
ALKSAlkermes$30.75$37.5021.95%Hold
PCRXPacira BioSciences$19.83$23.7519.77%Hold
NBIXNeurocrine Biosciences$136.69$156.1414.23%Buy
PBHPrestige Consumer Healthcare$80.39$89.5011.33%Buy
ITCIIntra-Cellular Therapies$86.96$93.337.33%Buy
PAHCPhibro Animal Health$22.34$18.67-16.43%Buy

ALKS Forecast FAQ

Is Alkermes a good buy?

No, according to 9 Wall Street analysts, Alkermes (ALKS) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 44.44% of ALKS's total ratings.

What is ALKS's price target?

Alkermes (ALKS) average price target is $37.5 with a range of $36 to $40, implying a 26.22% from its last price of $29.71. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Alkermes stock go up soon?

According to Wall Street analysts' prediction for ALKS stock, the company can go up by 26.22% (from the last price of $29.71 to the average price target of $37.5), up by 34.63% based on the highest stock price target, and up by 21.17% based on the lowest stock price target.

Can Alkermes stock reach $40?

ALKS's average twelve months analyst stock price target of $37.5 does not support the claim that Alkermes can reach $40 in the near future.

What is Alkermes's current price target trend?

1 Wall Street analyst forecast a $37 price target for Alkermes (ALKS) this month, up 24.54% from its last price of $29.71. Compared to the last 3 and 12 months, the average price target increased by 17.81% and increased by 11.07%, respectively.

What are Alkermes's analysts' financial forecasts?

Alkermes's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.52B (high $1.54B, low $1.48B), average EBITDA is $-86.913M (high $-48.468M, low $-126M), average net income is $76.71M (high $162.74M, low $-18.442M), average SG&A $747.91M (high $760.35M, low $731.53M), and average EPS is $2.73 (high $2.94, low $2.48). ALKS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.41B (high $1.48B, low $1.32B), average EBITDA is $118.84M (high $125.23M, low $111.42M), average net income is $294.97M (high $335.07M, low $261.25M), average SG&A $694.17M (high $731.45M, low $650.81M), and average EPS is $1.77 (high $2.01, low $1.56).

Did the ALKS's actual financial results beat the analysts' financial forecasts?

Based on Alkermes's last annual report (Dec 2022), the company's revenue was $1.11B, beating the average analysts forecast of $1.09B by 2.36%. Apple's EBITDA was $-96.151M, beating the average prediction of $-53.976M by 78.14%. The company's net income was $-158M, missing the average estimation of $-312M by -49.24%. Apple's SG&A was $605.75M, beating the average forecast of $536.15M by 12.98%. Lastly, the company's EPS was $-0.97, missing the average prediction of $0.0994 by -1075.61%. In terms of the last quarterly report (Dec 2023), Alkermes's revenue was $377.48M, beating the average analysts' forecast of $362.22M by 4.21%. The company's EBITDA was $54.63M, beating the average prediction of $30.61M by 78.47%. Alkermes's net income was $160.55M, beating the average estimation of $74.73M by 114.84%. The company's SG&A was $169.79M, missing the average forecast of $178.8M by -5.04%. Lastly, the company's EPS was $0.96, beating the average prediction of $0.447 by 114.56%